The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
- 19 May 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (10) , 1770-1772
- https://doi.org/10.1016/j.ejca.2010.04.010
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The postchemotherapy PSA surge syndromeAnnals of Oncology, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 StudyEuropean Urology, 2008
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxelCancer, 2007
- Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient dataThe Lancet Oncology, 2007
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisonsBJU International, 2002